Beta Bionics Inc
Research Beta Bionics Inc (BBNX) on Bullrun: market cap USD 793.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBBNX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 793.03M
- Financial periodQ2 2026
- RevenueUSD 32.01M
- Net income-USD 23.40M
- Free cash flow-USD 15.66M
- Gross margin59.0%
Valuation Snapshot
latest market cap is USD 793.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 100.25M | -USD 73.20M | -USD 56.22M | 55.4% | -1.81 | USD 31.58M | USD 7.30M | USD 287.61M |
| FY2024 | USD 65.12M | -USD 54.76M | -USD 51.67M | 55.1% | -8.6 | USD 30.43M | USD 7.26M | -USD 245.36M |
| FY2023 | USD 12.00M | -USD 44.10M | -USD 32.85M | 52.6% | -8.31 | USD 26.57M | USD 4.22M | -USD 203.11M |
| FY2022 | USD 179.00K | -USD 64.75M | -USD 60.98M | 100.0% | -2.12 | USD 27.68M | USD 4.13M | -USD 170.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 793.03M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.35B | n/a | n/a | n/a |
About Beta Bionics Inc
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Beta Bionics Inc's market cap?
Beta Bionics Inc's market capitalization is USD 793.03M.
What does Beta Bionics Inc do?
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.